{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T14:10:14Z","timestamp":1791382214793,"version":"4.3.3"},"reference-count":52,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2026,1,11]],"date-time":"2026-01-11T00:00:00Z","timestamp":1768089600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015326","name":"NIH","doi-asserted-by":"publisher","award":["R01-NS126187"],"award-info":[{"award-number":["R01-NS126187"]}],"id":[{"id":"10.13039\/100015326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015326","name":"NIH","doi-asserted-by":"publisher","award":["R01-DC020724"],"award-info":[{"award-number":["R01-DC020724"]}],"id":[{"id":"10.13039\/100015326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"Department of Defense New Investigator Award","doi-asserted-by":"publisher","award":["W81XWH-16-1-0219"],"award-info":[{"award-number":["W81XWH-16-1-0219"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"Investigator-Initiated Research Award","doi-asserted-by":"publisher","award":["W81XWH-20-1-0222"],"award-info":[{"award-number":["W81XWH-20-1-0222"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"Clinical Trial Award","doi-asserted-by":"publisher","award":["W81XWH2210439"],"award-info":[{"award-number":["W81XWH2210439"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Children\u2019s Tumor Foundation Drug Discovery Initiative"},{"name":"Children\u2019s Tumor Foundation Clinical Research Award"},{"DOI":"10.13039\/100000048","name":"American Cancer Society Mission Boost Award","doi-asserted-by":"publisher","award":["MBGII-24-1255260-01-MBG"],"award-info":[{"award-number":["MBGII-24-1255260-01-MBG"]}],"id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>NF2-related Schwannomatosis (NF2-SWN) remains a disorder with few effective treatment options. Patients develop vestibular schwannomas (VSs) on both auditory nerves, which gradually impair hearing and often result in significant communication difficulties, social withdrawal, and higher rates of depression. Progress in understanding NF2-SWN biology and translating discoveries into therapies has been slowed by the absence of robust animal models that faithfully reproduce both tumor behavior and the associated neurological deficits. In this review, we summarized the development of animal models that not only reproduce tumor growth in the peripheral nerve microenvironment but also reproduce tumor-induced neurological symptoms, such as hearing loss and ataxia. We further highlight the currently available organotypic models for NF2-SWN. Together, these systems provide an essential foundation for advancing mechanistic studies and accelerating the development of effective therapies for this devastating disorder.<\/jats:p>","DOI":"10.3390\/cancers18020224","type":"journal-article","created":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T07:30:34Z","timestamp":1768203034000},"page":"224","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Advancements in Preclinical Models for NF2-Related Schwannomatosis Research"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-5817-9586","authenticated-orcid":false,"given":"Bo-Shi","family":"Zhang","sequence":"first","affiliation":[{"name":"Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simeng","family":"Lu","sequence":"additional","affiliation":[{"name":"Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6109-6419","authenticated-orcid":false,"given":"Scott R.","family":"Plotkin","sequence":"additional","affiliation":[{"name":"Department of Neurology and Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0525-183X","authenticated-orcid":false,"given":"Lei","family":"Xu","sequence":"additional","affiliation":[{"name":"Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,1,11]]},"reference":[{"key":"ref_1","first-page":"603","article-title":"A clinical study of type 2 neurofibromatosis","volume":"84","author":"Evans","year":"1992","journal-title":"Q J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e50","DOI":"10.1097\/MAO.0000000000000239","article-title":"Natural History of Vestibular Schwannoma Growth and Hearing Decline in Newly Diagnosed Neurofibromatosis Type 2 Patients","volume":"35","author":"Plotkin","year":"2014","journal-title":"Otol. Neurotol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1097\/AUD.0000000000000238","article-title":"Revealing Hearing Loss: A Survey of How People Verbally Disclose Their Hearing Loss","volume":"37","author":"West","year":"2016","journal-title":"Ear Hear."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Kim, S.Y., Kim, H.-J., Park, E.-K., Joe, J., Sim, S., and Choi, H.G. (2017). Severe hearing impairment and risk of depression: A national cohort study. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0179973"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1056\/NEJMoa0902579","article-title":"Hearing Improvement after Bevacizumab in Patients with Neurofibromatosis Type 2","volume":"361","author":"Plotkin","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"3446","DOI":"10.1200\/JCO.19.01367","article-title":"Multicenter, Prospective, Phase II and Biomarker Study of High-Dose Bevacizumab as Induction Therapy in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannoma","volume":"37","author":"Plotkin","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1097\/MAO.0b013e31825e73f5","article-title":"Bevacizumab for Progressive Vestibular Schwannoma in Neurofibromatosis Type 2: A Retrospective Review of 31 Patients","volume":"33","author":"Plotkin","year":"2012","journal-title":"Otol. Neurotol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1101\/gad.12.8.1121","article-title":"Mice heterozygous for a mutation at the Nf2 tumor suppressor locus develop a range of highly metastatic tumors","volume":"12","author":"McClatchey","year":"1998","journal-title":"Genes Dev."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1101\/gad.14.13.1617","article-title":"Conditional biallelic Nf2 mutation in the mouse promotes manifestations of human neurofibromatosis type 2","volume":"14","author":"Giovannini","year":"2000","journal-title":"Genes Dev."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/hmg\/ddu414","article-title":"A murine model of neurofibromatosis type 2 that accurately phenocopies human schwannoma formation","volume":"24","author":"Gehlhausen","year":"2015","journal-title":"Hum. Mol. Genet"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/sj.neo.7900249","article-title":"Mouse Models of Neurofibromatosis 1 and 2","volume":"4","author":"Gutmann","year":"2002","journal-title":"Neoplasia"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"M73","DOI":"10.1016\/S0304-419X(00)00026-3","article-title":"Mouse models of neurofibromatosis","volume":"1471","author":"McClatchey","year":"2001","journal-title":"Biochim. et Biophys. Acta (BBA) Rev. Cancer"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1097\/01.mlg.0000240185.14224.7d","article-title":"Growth of Benign and Malignant Schwannoma Xenografts in Severe Combined Immunodeficiency Mice","volume":"116","author":"Chang","year":"2006","journal-title":"Laryngoscope"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s00401-016-1583-8","article-title":"The importance of nerve microenvironment for schwannoma development","volume":"132","author":"Schulz","year":"2016","journal-title":"Acta Neuropathol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3483","DOI":"10.1158\/0008-5472.CAN-09-3107","article-title":"Anti\u2013Vascular Endothelial Growth Factor Therapies as a Novel Therapeutic Approach to Treating Neurofibromatosis-Related Tumors","volume":"70","author":"Wong","year":"2010","journal-title":"Cancer Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jneumeth.2010.10.021","article-title":"A novel imaging-compatible sciatic nerve schwannoma model","volume":"195","author":"Saydam","year":"2011","journal-title":"J. Neurosci. Methods"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"14676","DOI":"10.1073\/pnas.1512570112","article-title":"Anti-VEGF treatment improves neurological function and augments radiation response in NF2 schwannoma model","volume":"112","author":"Gao","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"848","DOI":"10.3892\/ijo.2013.1798","article-title":"Microarray analysis of gene expression in vestibular schwannomas reveals SPP1\/MET signaling pathway and androgen receptor deregulation","volume":"42","author":"Lassaletta","year":"2013","journal-title":"Int. J. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"54515","DOI":"10.18632\/oncotarget.10248","article-title":"Crizotinib inhibits NF2-associated schwannoma through inhibition of focal adhesion kinase 1","volume":"7","author":"Troutman","year":"2016","journal-title":"Oncotarget"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1128\/MCB.01392-08","article-title":"The Neurofibromatosis 2 Protein, Merlin, Regulates Glial Cell Growth in an ErbB2- and Src-Dependent Manner","volume":"29","author":"Houshmandi","year":"2009","journal-title":"Mol. Cell. Biol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1158\/1535-7163.MCT-17-0417","article-title":"Combination Therapy with c-Met and Src Inhibitors Induces Caspase-Dependent Apoptosis of Merlin-Deficient Schwann Cells and Suppresses Growth of Schwannoma Cells","volume":"16","author":"Fuse","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"4211","DOI":"10.1038\/s41598-020-60156-6","article-title":"Combination therapy with mTOR kinase inhibitor and dasatinib as a novel therapeutic strategy for vestibular schwannoma","volume":"10","author":"Sagers","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"117585","DOI":"10.1016\/j.biopha.2024.117585","article-title":"Physiological and tumor-associated angiogenesis: Key factors and therapy targeting VEGF\/VEGFR pathway","volume":"180","author":"Lorenc","year":"2024","journal-title":"Biomed. Pharmacother."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1093\/neuonc\/noz153","article-title":"EANO guideline on the diagnosis and treatment of vestibular schwannoma","volume":"22","author":"Goldbrunner","year":"2020","journal-title":"Neuro-Oncology"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"51","DOI":"10.29245\/2572-9411\/2016\/2.1042","article-title":"Rationally combining anti-VEGF therapy with radiation in NF2 schwannoma","volume":"1","author":"Zhang","year":"2016","journal-title":"J. Rare Dis. Res. Treat."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1089\/hum.2012.094","article-title":"Regression of Schwannomas Induced by Adeno-Associated Virus-Mediated Delivery of Caspase-1","volume":"24","author":"Prabhakar","year":"2013","journal-title":"Hum. Gene Ther."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/s41417-018-0077-3","article-title":"Schwannoma gene therapy by adeno-associated virus delivery of the pore-forming protein Gasdermin-D","volume":"26","author":"Ahmed","year":"2019","journal-title":"Cancer Gene Ther."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.omtm.2022.06.012","article-title":"Gene replacement therapy in a schwannoma mouse model of neurofibromatosis type 2","volume":"26","author":"Prabhakar","year":"2022","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s11060-016-2150-9","article-title":"An allograft mouse model for the study of hearing loss secondary to vestibular schwannoma growth","volume":"129","author":"Bonne","year":"2016","journal-title":"J. Neuro-Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e362","DOI":"10.1097\/MAO.0000000000001766","article-title":"A Xenograft Model of Vestibular Schwannoma and Hearing Loss","volume":"39","author":"Dinh","year":"2018","journal-title":"Otol. Neurotol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1097\/MAO.0000000000003556","article-title":"Effect of AR42 in Primary Vestibular Schwannoma Cells and a Xenograft Model of Vestibular Schwannoma","volume":"43","author":"Misztal","year":"2022","journal-title":"Otol. Neurotol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/s41596-018-0105-7","article-title":"A cerebellopontine angle mouse model for the investigation of tumor biology, hearing, and neurological function in NF2-related vestibular schwannoma","volume":"14","author":"Chen","year":"2019","journal-title":"Nat. Protoc."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"E2077","DOI":"10.1073\/pnas.1719966115","article-title":"Targeting the cMET pathway augments radiation response without adverse effect on hearing in NF2 schwannoma models","volume":"115","author":"Zhao","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Wu, L., Vasilijic, S., Sun, Y., Chen, J., Landegger, L.D., Zhang, Y., Zhou, W., Ren, J., Early, S., and Yin, Z. (2021). Losartan prevents tumor-induced hearing loss and augments radiation efficacy in NF2 schwannoma rodent models. Sci. Transl. Med., 13.","DOI":"10.1126\/scitranslmed.abd4816"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1007\/s00415-014-7303-1","article-title":"Longitudinal evaluation of quality of life in 288 patients with neurofibromatosis 2","volume":"261","author":"Ferner","year":"2014","journal-title":"J. Neurol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"fcad089","DOI":"10.1093\/braincomms\/fcad089","article-title":"Vestibular dysfunction in NF2\u2013related schwannomatosis","volume":"5","author":"Madhani","year":"2023","journal-title":"Brain Commun."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Lu, S., Yin, Z., Chen, J., Wu, L., Sun, Y., Gao, X., Huang, P., Jordan, J.T., Plotkin, S.R., and Xu, L. (2024). Integrating Ataxia Evaluation into Tumor-Induced Hearing Loss Model to Comprehensively Study NF2-Related Schwannomatosis. Cancers, 16.","DOI":"10.3390\/cancers16111961"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1002\/path.5908","article-title":"Novel patient-derived xenograft and cell line models for therapeutic screening in NF2-associated schwannoma","volume":"257","author":"Zhao","year":"2022","journal-title":"J. Pathol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1002\/cncr.35279","article-title":"Evolving concepts in meningioma management in the era of genomics","volume":"130","author":"Hsieh","year":"2024","journal-title":"Cancer"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/978-1-4939-3615-1_4","article-title":"Generation of noninvasive, quantifiable, orthotopic animal models for nf2-associated schwannoma and meningioma","volume":"1427","author":"Burns","year":"2016","journal-title":"Methods Mol. Biol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"e70287","DOI":"10.1111\/cns.70287","article-title":"Cas9 Mouse Model of Skull Base Meningioma Driven by Combinational Gene Inactivation in Meningeal Cells","volume":"31","author":"Tang","year":"2025","journal-title":"CNS Neurosci. Ther."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.18632\/oncotarget.2810","article-title":"Group I Paks as therapeutic targets in NF2-deficient meningioma","volume":"6","author":"Chow","year":"2015","journal-title":"Oncotarget"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1093\/neuonc\/noy046","article-title":"EPH receptor signaling as a novel therapeutic target in NF2-deficient meningioma","volume":"20","author":"Angus","year":"2018","journal-title":"Neuro-Oncology"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Chang, L.-S., Oblinger, J.L., Smith, A.E., Ferrer, M., Angus, S.P., Hawley, E., Petrilli, A.M., Beauchamp, R.L., Riecken, L.B., and Erdin, S. (2021). Brigatinib causes tumor shrinkage in both NF2-deficient meningioma and schwannoma through inhibition of multiple tyrosine kinases but not ALK. PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0252048"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1158\/0008-5472.CAN-12-1888","article-title":"Histone Deacetylase Inhibitor AR-42 Differentially Affects Cell-cycle Transit in Meningeal and Meningioma Cells, Potently Inhibiting NF2-Deficient Meningioma Growth","volume":"73","author":"Burns","year":"2013","journal-title":"Cancer Res."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1093\/neuonc\/nor072","article-title":"AR42, a novel histone deacetylase inhibitor, as a potential therapy for vestibular schwannomas and meningiomas","volume":"13","author":"Bush","year":"2011","journal-title":"Neuro-Oncology"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"vdae024","DOI":"10.1093\/noajnl\/vdae024","article-title":"Preclinical evaluation of the third-generation, bi-steric mechanistic target of rapamycin complex 1-selective inhibitor RMC-6272 in NF2-deficient models","volume":"6","author":"Bhattacharyya","year":"2024","journal-title":"Neuro-Oncol. Adv."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1093\/neuonc\/now031","article-title":"A new patient-derived orthotopic malignant meningioma model treated with oncolytic herpes simplex virus","volume":"18","author":"Nigim","year":"2016","journal-title":"Neuro-Oncology"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1093\/neuonc\/noab114","article-title":"MEF2C silencing downregulates NF2 and E-cadherin and enhances Erastin-induced ferroptosis in meningioma","volume":"23","author":"Bao","year":"2021","journal-title":"Neuro-Oncology"},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Landegger, L.D., Dilwali, S., and Stankovic, K.M. (2017). Neonatal Murine Cochlear Explant Technique as an In Vitro Screening Tool in Hearing Research. J. Vis. Exp., e55704.","DOI":"10.3791\/55704-v"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"vdaa153","DOI":"10.1093\/noajnl\/vdaa153","article-title":"New developments in neurofibromatosis type 2 and vestibular schwannoma","volume":"3","author":"Ren","year":"2020","journal-title":"Neuro-Oncol. Adv."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"18599","DOI":"10.1038\/srep18599","article-title":"Secreted Factors from Human Vestibular Schwannomas Can Cause Cochlear Damage","volume":"5","author":"Dilwali","year":"2015","journal-title":"Sci. Rep."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/2\/224\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T07:34:48Z","timestamp":1768203288000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/2\/224"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,11]]},"references-count":52,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["cancers18020224"],"URL":"https:\/\/doi.org\/10.3390\/cancers18020224","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,11]]}}}